In conclusion, we have developed and validated a highly sensitive and selective method for measuring Q-1802 in ICR mouse serum. The development and validation steps of assays met the required criteria for validation, which suggested that these can be applied to quantify Q-1802, as well as in PK studies.
Interim data from the present phase 1 study, demonstrate that Q-1802 has excellent preliminary safety, tolerability and preliminary anti-tumor activity up to doses of 20 mg/kg. The dose extension is still ongoing. Clinical trial information: NCT04856150.
almost 2 years ago
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)